~~<i id='4AC056AF00'><strike id='4AC056AF00'><tt id='4AC056AF00'><pre id='4AC056AF00'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

hotspot

author：explore 2025-09-06 04:30:10 - browse：7

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： UCSF medical school apologizes for unethical prisoner experiments

focus

explore

knowledge

focus

knowledge

hotspot

Scanningelectronmicrographofhumanrespiratorysyncytialvirus.NIAIDApanelofexperts thatadvisestheCenter

WSS

Diversify hospital leadership teams to protect BIPOC patient health

A clever new way to fix Medicaid and graduate medical education

How Long Island became the ‘eugenics capital of the world’

Feds fine Medicare Advantage plans for overcharging members

Neuroscience startup Neumora files for IPO

Australia’s approach to dialysis celebrates life

Wikipedia

hotspot

focus

How one medical school became remarkably diverse

What AAP's gender

BioMarin wins approval for gene therapy to treat hemophilia A

AstraZeneca challenges Medicare drug negotiation program

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Appeals court upholds limits to abortion pill

Heart attack and stroke risk calculators need revising

Victims of gun violence feel impacts long after bullet wound

Medicare proposal to cover medical devices draws a mixed reaction

Medicare will require more price transparency from hospitals

explore

Neuroscience startup Neumora files for IPO

More doctors should go into startup world

FDA approves Recor Medical high blood pressure device

FDA approves Recor Medical high blood pressure device

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Diversity in medical illustrations gets boost from Chidiebere Ibe

knowledge

focus

knowledge

hotspot